IM HealthScience® aspires to become the leading Medical Foods innovator. Its present focus is on the underserved patients with gastrointestinal conditions. Areas of high unmet medical need include IBS, Functional Dyspepsia, Diverticulosis, Ulcerative Colitis, and Crohn’s Disease. These are priority areas for IMH research.
IMH launched IBgard® nationally in 2015 for patients with IBS. IBgard has been very well received by patients who have given their feedback to their physicians. In the meantime, the medical consensus around IBgard and its utility in IBS has been further strengthened by the emergence of three important studies, IBSREST™, IBSRRET™ and IBSACT™ presented at DDW, AGA and ACG. This medical consensus has been further confirmed by the formal approval of IBgard by Health Canada in 2015.
IMH launched FDgard® nationally in May of 2016 for patients with Functional Dyspepsia (FD). Also known as non-ulcerative dyspepsia, the main symptoms of FD are early fullness with meals, upper belly pain, nausea, bloating and belching. Currently there are no other over the counter products, prescription products or medical foods for patients with Functional Dyspepsia. IMH developed FDgard® using its SST® (Site Specific Targeting) technology to deliver a well understood and clinically studied combination of ingredients.